STOCK TITAN

IDEXX (IDXX) EVP Nimrata Hunt details new grants and RSU vesting

Filing Impact
(Very High)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

IDEXX Laboratories Executive Vice President Nimrata Hunt reported multiple equity awards, vesting events, and related share withholdings. On February 12, 2026, Hunt received grants of 4,625 non-qualified stock options, 162 incentive stock options, and restricted stock units covering 1,094 and 1,620 shares of common stock.

On February 14, 2026, several restricted stock unit awards were exercised or converted, delivering a total of 2,587 shares of common stock, while 1,154 shares were withheld at $629.35 per share to satisfy tax obligations. After these transactions, Hunt directly owned 22,591.944 shares and indirectly held 160 shares jointly with a spouse.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hunt Nimrata

(Last) (First) (Middle)
ONE IDEXX DRIVE

(Street)
WESTBROOK ME 04092

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
IDEXX LABORATORIES INC /DE [ IDXX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Executive Vice President
3. Date of Earliest Transaction (Month/Day/Year)
02/12/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 02/14/2026 M 204 A $0 21,362.944(1) D
Common Stock 02/14/2026 M 207 A $0 21,569.944 D
Common Stock 02/14/2026 M 301 A $0 21,870.944 D
Common Stock 02/14/2026 M 1,508 A $0 23,378.944 D
Common Stock 02/14/2026 M 367 A $0 23,745.944 D
Common Stock 02/14/2026 F 1,154 D $629.35(2) 22,591.944 D
Common Stock 160 I jointly with spouse
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Non-Qualified Stock Option (right-to-buy) $617.2 02/12/2026 A 4,625 (3) 02/11/2036 Common Stock 4,625 $0 4,625 D
Incentive Stock Option (right-to-buy) $617.2 02/12/2026 A 162 (4) 02/11/2036 Common Stock 162 $0 162 D
Restricted Stock Unit (5) 02/12/2026 A 1,094 (5) (5) Common Stock 1,094 $0 1,094 D
Restricted Stock Unit (6) 02/12/2026 A 1,620 (6) (6) Common Stock 1,620 $0 1,620 D
Restricted Stock Unit (7) 02/14/2026 M 204 (7) (7) Common Stock 204 $0 0 D
Restricted Stock Unit (8) 02/14/2026 M 207 (8) (8) Common Stock 207 $0 207 D
Restricted Stock Unit (9) 02/14/2026 M 301 (9) (9) Common Stock 301 $0 602 D
Restricted Stock Unit (10) 02/14/2026 M 367 (10) (10) Common Stock 367 $0 1,101 D
Restricted Stock Unit (11) 02/14/2026 M 1,508 (11) (11) Common Stock 1,508 $0 0 D
Explanation of Responses:
1. 1. Includes 10 shares purchased under the Issuer Employee Stock Purchase Plan ('ESPP') on December 31, 2025. There are a total of 401.944 shares held in the ESPP which has been increased by 0.005 shares due to a rounding calculation of previously issued fractional shares.
2. Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026.
3. Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027.
4. Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030.
5. Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027.
6. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in three annual installments, beginning February 14, 2027.
7. Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments, beginning February 14, 2023.
8. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024.
9. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025.
10. Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026.
11. Each RSU represents a contingent right to receive one share of Issuer common stock and vested in one installment on February 14, 2026.
Remarks:
/s/ Lily J. Lu, Attorney-in-Fact for Nimrata Hunt 02/17/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did IDEXX (IDXX) EVP Nimrata Hunt report?

Executive Vice President Nimrata Hunt reported option and restricted stock unit grants, RSU vesting into common shares, and share withholdings for taxes. These transactions increased her direct and indirect ownership in IDEXX Laboratories common stock while settling tax liabilities in shares.

How many IDEXX (IDXX) stock options were granted to Nimrata Hunt?

Hunt received grants of 4,625 non-qualified stock options and 162 incentive stock options. According to footnotes, these options become exercisable in installments beginning February 14, 2027 and on February 14, 2030, aligning vesting with multi-year executive compensation schedules.

What restricted stock unit awards did Nimrata Hunt receive from IDEXX (IDXX)?

Hunt was granted restricted stock units covering 1,094 shares and 1,620 shares of IDEXX common stock. Footnotes state each RSU converts into one share and vests over three or four annual installments starting February 14, 2027, linking equity rewards to continued service.

How many IDEXX (IDXX) shares did Nimrata Hunt receive from RSU vesting?

On February 14, 2026, several restricted stock unit awards were exercised or converted into 2,587 shares of IDEXX common stock. These vesting events reflect previously granted RSUs reaching their scheduled vesting dates under the company’s long-term incentive plans.

Why were 1,154 IDEXX (IDXX) shares disposed of in Nimrata Hunt’s Form 4?

The filing shows 1,154 shares treated as a disposition at $629.35 per share to satisfy tax obligations by delivering shares. A footnote states this price was the IDEXX closing price on February 13, 2026, indicating a tax-withholding mechanism rather than an open-market sale.

What is Nimrata Hunt’s IDEXX (IDXX) share ownership after these transactions?

Following the reported grants, vesting, and tax withholdings, Hunt directly owned 22,591.944 shares of IDEXX common stock. She also indirectly held 160 additional shares jointly with her spouse, reflecting combined family ownership disclosed in the Form 4.
IDEXX Laboratories

NASDAQ:IDXX

IDXX Rankings

IDXX Latest News

IDXX Latest SEC Filings

IDXX Stock Data

50.36B
79.30M
Diagnostics & Research
In Vitro & in Vivo Diagnostic Substances
Link
United States
WESTBROOK